EMEA-000399-PIP01-08

Key facts

Invented name
Imprida HCT
Active substance
  • valsartan
  • hydrochlorothiazide
  • Amlodipine besilate
Therapeutic area
Cardiovascular diseases
Decision number
P/16/2009
PIP number
EMEA-000399-PIP01-08
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Essential hypertension
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Ltd.

E-mail: paediatric.enquiries@novartis.com 
Country: Switzerland
Phone: +41 613246715
Fax: +41 613242224

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating